Polymorphism is a major concern for the pharmaceutical industry. Everything from efficacy to regulatory applications and intellectual property can be affected by a lack of polymorphic control over an API.
Aug 25, 2019 CrystecUK
The quality of an inhalable formulation is judged on three key properties:
- Emitted Dose (ED): the amount of formulation which leaves the inhaler/device
- Fine Particle Fraction (FPF): the percentage of drug which reaches and stays in…
Jun 25, 2019 CrystecUK